DV
Dividend Vision

RGNX — Regenxbio Inc

Regenxbio Inc (RGNX)

Total return is -64.6% over the past 10.9 years, 430.8 points behind SPY at 366.2%. Its deepest 1-year drawdown was 64.6%.

RGNX is a single-stock equity holding in Regenxbio Inc, a biotechnology company focused on gene therapy development. As a individual stock rather than a diversified fund, it does not have a stated dividend distribution rate, expense ratio, or fund-level yield profile typical of ETFs. This holding appeals to investors seeking direct exposure to a specific biotech company's growth potential rather than those primarily focused on current income generation.

RGNX key facts

Asset type
Stock
Asset class
Equity
Inception date
09/17/2015
Last close
$10.77
Market cap
$557,448,768
Average volume
792500.0
Beta
0.901
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.84